Limitations of our study include that—while we observe a specific downregulation of DNMT3A in IECs from IBD patients- for reasons of informed consent, we cannot directly link this effect to the genetic background of the respective patient population. The gene discussed is DNMT3A; the disease is inflammatory bowel disease.